PHE News

Precision for Medicine Acquires Precision Health Economics

Extends Leadership in Health Economics and Outcomes Research With a Focus on Evidence Generation in an Era of Precision Medicine.

Precision for Medicine, a specialized services company supporting next-generation approaches to drug development and commercialization, today announced the acquisition of Precision Health Economics (PHE).


Precision in Bioprocess Online

Precision’s Deb Phippard, PhD, and Jared Kohler, PhD, address the potential of Big Data, analytics, and technology to increase efficiency and decrease costs in the drug development process in a guest column for Bioprocess Online.


Precision's Renick and Blandford in Value Based Cancer Care Magazine

Precision’s Dan Renick and Larry Blandford discuss the implications of the new provider-driven value assessment tools in oncology in the July issue of Value Based Cancer Care magazine.


Philipson in Forbes: California's Vaccination Mandate

Tomas Philipson's latest Op-Ed focuses on California's vaccination mandate and the application of economic epidemiology.


Precision's Ton Teaches At NIH

Precision Associate Director and Senior Research Epidemiologist Thanh Ton has been selected by the National Institutes of Health to teach data management and analysis at the NIH/Fogarty Global Health Program for Scholars and Fellows, to be held July 10-15th in Bethesda, MD.

  • Academic Insights at

    the Speed of Business

  • Intellectual Integrity

    Led by professors at elite research universities, we bring intellectual integrity, academic rigor, and a creative approach to the most challenging problems in heath care.

  • Real World Impact

    PHE recommendations have defined and changed national and international payment policies.

  • Unparalleled Influence

    We frequently appear in top-tier publications and media outlets-- our work reaches top decision makers and influences outcomes.

  • Evidence Generation and

    Commercial Excellence

    As part of Precision for Medicine, our academic approach to research can be linked with a tailored, commercial approach that demonstrates the value of innovative medications.

  • Academic Insights at

    the Speed of Business